Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
394 stopped studies mapped to Hepatocellular Carcinoma and descendants · 93% state a reason
Over the 394 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | Phase 3 | terminated | Jul 29, 2011 | National Cancer Institute, Naples | lack of enrolment | Enrollment / accrual |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Phase 1 | terminated | Dec 24, 2014 | Celgene | Slow enrollment and business decision. No safety concerns were identified for the study drugs. | Safety / toxicity |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | Phase 2 | terminated | Dec 18, 2007 | University of Pittsburgh | Bayer Healthcare is no supplying the study drug | Other (stated, no rule matched) |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | — | terminated | Jul 15, 2010 | Stanford University | accrual | Enrollment / accrual |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | Phase 3 | terminated | Dec 18, 2014 | Assistance Publique - Hôpitaux de Paris | Decision of investigator | Investigator |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2011 | Philipps University Marburg | not stated | Not stated |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | Phase 2 | terminated | Jan 29, 2007 | National Cancer Institute (NCI) | The study was stopped prior to 2nd stage. | Other (stated, no rule matched) |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | Phase 2 | withdrawn | Oct 17, 2013 | Novartis Pharmaceuticals | Study was cancelled by Sponsor. | Other (stated, no rule matched) |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Nov 26, 2009 | Stanford University | enrollment was too low | Enrollment / accrual |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Sep 3, 2009 | National Health Research Institutes, Taiwan | Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early… | Other (stated, no rule matched) |
| NCT01480817 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | Phase 2 | terminated | Nov 29, 2011 | Seoul National University Hospital | Difficulty of participant enrollment. | Enrollment / accrual |
| NCT01857726 | Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With… | N/A | withdrawn | May 20, 2013 | Seoul National University Hospital | No participants were enrolled | Enrollment / accrual |
| NCT01953406 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of… | Phase 2 | withdrawn | Oct 1, 2013 | Seoul National University Hospital | No participants were enrolled. Therefore, we stop this study, prematurely. | Enrollment / accrual |
| NCT02004210 | A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma | Phase 3 | withdrawn | Dec 9, 2013 | Seoul National University Hospital | No participants were enrolled. | Enrollment / accrual |
| NCT01875549 | Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary… | N/A | withdrawn | Jun 12, 2013 | Kwang Hyuck Lee | no enrollment | Enrollment / accrual |
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | Phase 2 | terminated | Mar 8, 2013 | Emory University | Primary endpoint not met | Other (stated, no rule matched) |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary… | Phase 2 | terminated | Dec 28, 2007 | The University of Texas Medical Branch, Galveston | recruiting or enrolling participants has halted prematurely and will not resume; participants are… | Enrollment / accrual |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract… | Phase 2 | terminated | Sep 20, 2007 | Gabi Chiorean, MD | Terminated due to funding issues. | Funding |
| NCT00746655 | SBRT + TACE for Primary Hepatocellular Carcinoma | N/A | withdrawn | Sep 4, 2008 | University of Pittsburgh | Unable to recruit | Enrollment / accrual |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients… | Phase 1 | terminated | Apr 29, 2008 | Lisa H. Butterfield, Ph.D. | Poor accrual and limited target patient population for future accrual. Did not complete the Phase 1… | Enrollment / accrual |
| NCT02304445 | Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer(TACE-SBRT) | N/A | withdrawn | Dec 2, 2014 | Juan Sanabria, MD | Necessary equipment could not be obtained. | Other (stated, no rule matched) |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular… | Phase 1 | terminated | Jan 31, 2012 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01911273 | A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A… | Phase 2 | terminated | Jul 30, 2013 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01108705 | Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment…(BRISK-APS) | Phase 3 | terminated | Apr 22, 2010 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous… | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | Early termination for discouraging results | Other (stated, no rule matched) |
| NCT01968629 | 24hr Imaging Of HCC After EOVIST | Early Phase 1 | withdrawn | Oct 24, 2013 | Massachusetts General Hospital | No eligible subject enrolled | Enrollment / accrual |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of… | Phase 1 | terminated | May 5, 2011 | Indiana University | Treatment was ineffective | Other (stated, no rule matched) |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for… | Phase 2 | terminated | Feb 27, 2012 | Egyptian Society of Liver Cancer | After interim results data showed no evidence of a difference between both groups | Other (stated, no rule matched) |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular…(TRYPHON) | Phase 2 | terminated | Sep 18, 2012 | Jules Bordet Institute | poor recruitment and an unexpected low treatment rate | Enrollment / accrual |
| NCT02482909 | A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular… | N/A | terminated | Jun 26, 2015 | Seoul National University Hospital | The post-treatment recurrence rate was expected to be different between two treatment groups. | Other (stated, no rule matched) |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | Phase 2 | withdrawn | Jan 24, 2013 | University of Zurich | Lack of enrollment | Enrollment / accrual |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During… | — | terminated | Jan 11, 2012 | Medical University Innsbruck | Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of 10… | Enrollment / accrual |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Dec 10, 2009 | National Cancer Centre, Singapore | The phase II portion was not conducted due to funding issue. | Funding |
| NCT01801163 | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With… | Phase 1 | withdrawn | Feb 28, 2013 | Indiana University | Trial had no patients accrued while open | Enrollment / accrual |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible… | Phase 1 / Phase 2 | terminated | Apr 28, 2004 | Genzyme, a Sanofi Company | This study was terminated early by Genzyme because there were insufficient data to support clinical… | Other (stated, no rule matched) |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | Phase 2 | withdrawn | Feb 25, 2014 | Case Comprehensive Cancer Center | Principal Investigator left institution | Investigator |
| NCT00808145 | Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | withdrawn | Dec 15, 2008 | Lahey Clinic | Lack of enrollment, many screen failures and non eligible study participants | Enrollment / accrual |
| NCT01872988 | Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related… | Phase 3 | terminated | Jun 7, 2013 | Taichung Veterans General Hospital | Difficult in patient enrollment | Enrollment / accrual |
| NCT01722175 | Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or…(ALPPS) | Phase 2 | withdrawn | Nov 6, 2012 | Washington University School of Medicine | Safety concerns. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 9, 2017source: clinicaltrials